Previous close | 15.99 |
Open | N/A |
Bid | 47.60 |
Ask | 52.00 |
Strike | 170.00 |
Expiry date | 2024-06-21 |
Day's range | 15.99 - 15.99 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.